Skip to content

Author

G. Marchetti

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Virological outcomes, resistance profile and viral evolution of lenacapavir-based regimens in heavily treatment-experienced people: data from the PRESTIGIO Registry

Abstract Background Lenacapavir (LEN) is a first-in-class, long-acting HIV-1 capsid inhibitor, approved for the treatment of heavily treatment-experienced (HTE) people with HIV (PWH) with multidrug resistance (MDR). To date, few data are available on resistance profiles in real life. Methods Paired plasma and PBMC samp...

Maria Mercedes Santoro, D. Spalletta, V. Spagnuolo et al. · 0 citations
Oct 2026

Circulating SARS-CoV-2 RNA detection in acute COVID-19 disease and Post-COVID Condition.

OBJECTIVES To determine the clinical significance of circulating plasma SARS-CoV-2 RNA across acute COVID-19 and post-COVID condition (PCC) by investigating prevalence, determinants, and kinetics in a large longitudinal cohort, accounting for hospitalization and vaccination. METHODS We consecutively enrolled individu...

Roberta Rovito, L. Terracciano, Giuseppe De Pinto et al. · 0 citations
Open access Sep 2026

Beyond seropositivity: SARS-CoV-2 IgG responses in high-risk COVID-19 patients.

Findings highlight variant-specific limitations of anti-Spike IgG as a universal marker of protection and support the need for integrated serological and virological assessment to guide antiviral and monoclonal antibody strategies in vulnerable populations.

Matteo Domenico Marsiglia, Roberta Rovito, A. Amendola et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.